Responses
Poster Presentation
High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection
Compose a Response to This Article
Other responses
No responses have been published for this article.